Drug
Abexinostat clinical trials
Also written PCI-24781.
Includes 1 study of Abexinostat tosylate.
- studies test it
- 15
- open now
- 3
- in phase 3
- 1
- first study started
- 2005
Keep track of what changes. Save the abexinostat studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Studies by the year they started
15 studies that test it; most in 2018 (3)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2012 | 1 |
| 2018 | 3 |
| 2019 | 1 |
| 2020 | 3 |
| 2021 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 11
- Phase 2
- 6
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 9 · Other 6
Xynomic Pharmaceuticals, Inc. (5) · Pharmacyclics LLC. (4) · Pamela Munster (2) · Massachusetts General Hospital (1) · Memorial Sloan Kettering Cancer Center (1) · Rahul Aggarwal (1) · University of Nebraska (1)
Often tested with
Tested in the same studies.
Doxorubicin (1) · Ibrutinib (1) · Pembrolizumab (1) · Temozolomide (1) · Fulvestrant (1) · Palbociclib (1)
Studies
Open first, then newest update. How each study uses abexinostat is read from its arms, and is right about nine times in ten.
Testing it · 15
- A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent GliomaRecruitingPhase 1University of NebraskaNCT05698524Written as PCI 24781
- A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)RecruitingPhase 3Xynomic Pharmaceuticals, Inc.NCT03592472Written as Abexinostat
- Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)RecruitingPhase 2Xynomic Pharmaceuticals, Inc.NCT03936153Written as abexinostat
- PCI-24781 in Combination With Doxorubicin to Treat SarcomaCompletedPhase 1/2Massachusetts General HospitalNCT01027910Written as PCI-24781
- Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell LymphomaCompletedPhase 1Memorial Sloan Kettering Cancer CenterNCT03939182Written as Abexinostat
- A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular LymphomaActive, not recruitingPhase 2Xynomic Pharmaceuticals, Inc.NCT03934567Written as Abexinostat
- A Clinical Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Abexinostat in Chinese PatientsActive, not recruitingPhase 1/2Xynomic Pharmaceuticals, Inc.NCT04024696Written as Abexinostat
- Study of Abexinostat in Patients With Relapsed or Refractory Follicular LymphomaActive, not recruitingPhase 2Xynomic Pharmaceuticals, Inc.NCT03600441Written as Abexinostat
- Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid TumorsCompletedPhase 1Pamela MunsterNCT01543763Written as PZP115891, PCI-24781
- Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor MalignanciesCompletedPhase 1Rahul AggarwalNCT03590054Written as Abexinostat
- Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic CancerWithdrawnPhase 1Pamela MunsterNCT04498520Written as Abexinostat Tosylate
- Study of the Safety and Tolerability of PCI-24781 in Patients With LymphomaCompletedPhase 1/2Pharmacyclics LLC.NCT00724984Written as PCI-24781
- A Safety and Tolerability Study of PCI-24781 in Subjects With CancerCompletedPhase 1Pharmacyclics LLC.NCT01149668Written as PCI-24781
- Study of the Safety and Tolerability of Oral Capsule Form of PCI-24781 in Advanced Cancer PatientsCompletedPhase 1Pharmacyclics LLC.NCT00562224Written as PCI-24781
- Study of the Tolerability, Safety, and Pharmacokinetics of CRA-024781 in Cancer PatientsCompletedPhase 1Pharmacyclics LLC.NCT00473577Written as CRA-24781
Codes
What other systems call abexinostat · ClinicalTrials.gg INT004950
- MeSH (NLM) C512352abexinostatConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) IYO470654UABEXINOSTATConfirmed FDA, NLM, Wikidata
- Wikidata Q4667249abexinostatConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C68920AbexinostatOne source FDA
- DrugBank DB12565One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C512352 | abexinostat | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | IYO470654U | ABEXINOSTAT | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q4667249 | abexinostat | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C68920 | Abexinostat | One source FDA |
| DrugBank | DB12565 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.